Lunit to Supply 3D AI Breast Cancer Diagnostic Solution to Akumin in the U.S.

Lunit Signs Supply Agreement with Akumin for AI-Based 3D Breast Cancer Diagnostics
Expanding Access to Precision Cancer Screening Across the U.S. Through Akumin's Nationwide Network

Lunit, a medical artificial intelligence (AI) company led by CEO Seo Beomseok, announced on August 19 that it has signed a supply agreement with Akumin, a provider of imaging diagnostic services across the United States, for its 3D-based AI breast cancer diagnostic solution, "Lunit INSIGHT DBT."

Akumin, headquartered in Plantation, Florida, offers outsourced imaging diagnostics and cancer treatment services to healthcare institutions that face challenges in building such capabilities in-house. The company currently operates more than 150 imaging centers and numerous mobile medical imaging units across 47 states in the U.S., and maintains partnerships with over 1,000 healthcare institutions and physician groups.

Through this agreement, Lunit INSIGHT DBT will be supplied to Akumin. This product analyzes three-dimensional breast tomosynthesis (Digital Breast Tomosynthesis,·DBT) imaging data to assist healthcare professionals in making diagnoses. Notably, as the U.S. market for 3D breast imaging continues to grow, Lunit has been steadily increasing its market share. With Akumin's nationwide network, AI-based precision cancer diagnostic services are expected to reach even more patients. Akumin's decision to adopt this solution is part of its strategy to actively leverage advanced technologies to enhance the quality of care and expand patient access. Lunit also plans to accelerate its expansion within the U.S. imaging diagnostics network through this supply agreement.

Seo Beomseok, CEO of Lunit, stated, "While Lunit solutions are already being used in numerous imaging centers across the U.S., our partnership with Akumin, which provides innovative medical services nationwide, will enable even more patients to benefit from AI-based cancer diagnostics. Lunit will continue to focus on developing and disseminating AI solutions that address real needs in clinical settings, leading the transformation of the global cancer diagnostics paradigm."

Nasir Siddiqui, Chief Medical Officer (CMO) of Akumin, commented, "Lunit's AI solution delivers real value to both patients and healthcare professionals, backed by robust clinical data and proven performance in the field. With this adoption, Akumin's imaging diagnostic services will take a significant step forward in terms of customer satisfaction."

Meanwhile, the U.S. healthcare sector is currently facing structural challenges, including a surge in demand for screenings, a shortage of radiology specialists, high costs, and lengthy timelines associated with building in-house imaging facilities. In this context, the adoption of AI solutions by specialized companies like Akumin is expected to help address these issues by enabling more accurate and efficient diagnostic services with limited medical resources.

This content was produced with the assistance of AI translation services.